Long-term Anticoagulant Therapy after Myocardial Infarction in Women
Br Med J 1968; 3 doi: https://doi.org/10.1136/bmj.3.5618.571 (Published 07 September 1968) Cite this as: Br Med J 1968;3:571
- Chr. F. Borchgrevink,
- Chr. Bjerkelund,
- A. M. Abrahamsen,
- G. Bay,
- P. Borgen,
- B. Grande,
- I. Helle,
- H. Kjörstad,
- A. M. Petersen,
- T. Rörvik,
- R. Thorsen,
- A. Ödegaard
Abstract
A multicentre trial from five medical departments in Oslo has been carried out to determine the value in women patients of one year's long-term anticoagulant therapy. Follow-up long-term laboratory control and anticoagulant dosage were performed at one centre (the Rikshospitalet). One hundred and fifty-nine patients were assigned randomly into two similar well-matched groups (control and treatment). Dosage was controlled by Thrombotest, aiming at 10–20% levels, and 50% of the tests were less than 14%. Compared with the control group, the treatment group showed a significant reduction in mortality and in reinfarction rate. No serious bleeding complications occurred. It is concluded that women benefit as much as men from long-term anticoagulant therapy.
Footnotes
↵* From Medical Departments VII, VIII, and IX, Ullevål Sykehus; Medical Department A, Aker Sykehus; Krohgstötten Sykehus; and Institute for Thrombosis Research, Rikshospitalet, Oslo, Norway.